Drugs in the Pipeline
Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.
Drugs in the Pipeline
MK-2060 is an investigational monoclonal antibody designed to inhibit the activation of Factor XI and its ability to activate downstream proteins.
News
The prescribing information for Lokelma® (sodium zirconium cyclosilicate; AstraZeneca) has been updated to include a dosing regimen to treat hyperkalemia in patients with end-stage renal disease (ESRD) on chronic hemodialysis.
Drugs in the Pipeline
The FDA has granted Priority Review to dapagliflozin (Farxiga) for the treatment of new or worsening CKD.
Drugs in the Pipeline
The multicenter, event-driven, double-blind, placebo-controlled trial compared the effect of dapagliflozin to placebo on renal outcomes and cardiovascular mortality in patients with CKD.
Drugs in the Pipeline
The designation was granted based on results from the phase 3 DAPA-CKD trial, which was stopped early due to “overwhelming efficacy”.
News
The FDA has approved a new indication for Invokana (canagliflozin; Janssen) to reduce the risk of end-stage renal disease, doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure (HF) in adults with type 2 diabetes (T2D) and diabetic nephropathy with albuminuria >300mg/day.
Drugs in the Pipeline
The decision to stop the trial was made based on positive efficacy data following a recommendation from the study’s independent DMC.
News
In patients whose tumors had ESR1 mutations, elacestrant reduced the risk of progression or death by 45%.
News
EndoClot PHS is a single-use device consisting of a starch-based powder hemostat to control bleeding in the GI tract.
